Eli Lilly and Co. said its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival. The phase III study evaluated abemaciclib, a cyclin-dependent kinase 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer who have relapsed or progressed after endocrine therapy.
Mount Sinai hospital has formed a committee to investigate the ties between Jeffrey Epstein and Eva Dubin a leading doctor at the hospital and founder of the Dubin Breast Center at the Tisch Cancer Institute whose name is featured prominently in the Epstein files.
